Cell Robotics Announces Capitalization Plan

Dec 07, 2004, 00:00 ET from Cell Robotics International, Inc.

    ALBUQUERQUE, N.M., Dec. 7 /PRNewswire-FirstCall/ -- Cell Robotics
 International Inc. (OTC Bulletin Board:   CRII) announced today that in
 cooperation with major shareholders it has developed a capitalization plan to
 address the first significant stages of market entry for its recently
 redesigned products and continuation of new product development efforts.  The
 plan includes a working capital credit facility, the private placement of up
 to 3,400,000 shares of restricted common stock, the private placement of up to
 25,000 shares of a newly created class of preferred shares and debt to equity
     The Company has executed an agreement with its existing lender, F.A.
 Voight & Associates, to extend the maturity date of its working capital
 facility from December 2004 to July 2005 and to increase the facility from
 $1,000,000 to $2,000,000.  The new funding from the working capital facility
 will be provided in increments of $250,000 approximately every 30 days
 beginning on December 15, 2004 and ending on March 15, 2005.
     As a further vote of confidence in the Company, Voight & Associates have
 also agreed to convert $1,000,000 of the facility into equity after matching
 equity has been raised by the Company in the private placement.  Other lenders
 have indicated their intent to convert approximately $500,000 of current debt
 into equity as part of the funding plan.  If and when consummated, these
 actions could reduce the company's debt by approximately $1,500,000.
     To further strengthen the long tenured relationship between the Company
 and Voight & Associates the Company has asked, and Mr. Voight has accepted, an
 appointment to its Board of Directors.  Mr. Voight will be leading our renewed
 efforts and will focus on shareholder and investor communications.
     The funding plan is intended to simultaneously infuse capital while
 strengthening the Company's balance sheet.  If the plan is fully consummated,
 it will make available $1,000,000 in working capital included in new funding
 of up to approximately $2,500,000 from a combination of new common and
 preferred equity placement and conversion of the facility expansion into
     The Company intends to apply this capital to marketing and sales
 initiatives, such as the recently announced entry into the blood bank market,
 as well as to continue to pursue other activities such as hospitals, prisons
 and assisted living facilities, which have been inhibited strictly by lack of
     The Company will also extend the range of application of its laser
 microscopy products, including the emerging field of nanotechnology.  The
 Company's LaserTweezers(R) microscopy system has already proven useful for
 nanotechnology applications by at least one leading semiconductor
 manufacturer.  Further product improvements and designs for this field,
 resulting from ongoing discussions with prominent research scientists, are
 under development.
     In addition, the Company intends to pursue remaining tasks in the
 development of its Lasette product for infant heelsticks.  These tasks include
 market validation of current product designs and finalization of regulatory
 approvals.  Significant fundamental FDA approvals for the new product design
 have already been received.
     The Company's "Lasette" is a laser lancing device which is the only FDA
 cleared needle-free instrument available for collection of capillary blood
 samples by fingerstick procedure.  The Lasette now includes design features
 specifically directed to clinical applications; including screening tests and
 point-of-care blood analysis.  The P200 is now designed for fast and easy
 collection of capillary samples of up to 200 microliters (previously 75
 microliters).  Other improvements include doubling the maximum frequency of
 use, simplifying its operation and maintenance.  These and other improvements
 make the Lasette P200 especially well suited for applications at all clinical
     Cell Robotics International, Inc. is a medical laser products company.
 For further information, please visit the Company's web site at
 www.cellrobotics.com or www.Lasette.com.
     This press release includes certain statements that may be deemed to be
 "forward-looking statements" within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21E of the Securities Act of 1934 as
 amended.  All statements, other than statements of historical facts, included
 in this press release that address activities, events or developments that the
 Company expects, believes or anticipates will or may occur in the future are
 "forward-looking statements."  Such matters involve risks and uncertainties
 that may cause actual results to differ materially, including the following:
 changes in economic conditions; risks associated with the development of new
 products and markets; general competitive factors; the Company's ability to
 execute its service and product sales plans; the impact of current and future
 laws and government regulation, as well as repeal or modification of same,
 affecting the medical device industry and the Company's operations in
 particular; adequacy of our financial resources; obtaining and maintaining
 regulatory approval; the ability to retain key personnel and the risks
 described from time to time in the Company's Securities and Exchange
 Commission (SEC) filings.  For all these reasons, actual results or
 developments may differ materially from those projected in the
 "forward-looking statements."

SOURCE Cell Robotics International, Inc.